PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.

Derek Grose,Colin J. McKay,Susie Cooke,Janet Shirley Graham,Fraser Duthie,Nigel B. Jamieson,Reena Ravikumar,A. Duffton,David McIntosh,R.B. Goody,Ganesh Radhakrishna,Maria A. Hawkins,Dave Colville,Christine Willshire,Jon Stobo,James Paul,Sarah Bradley,Judith Dixon-Hughes,Andrew V. Biankin,David K. Chang,Andrew V. Biankin

PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.

2019

TPS4166Background: There is increasing evidence suggesting benefit from a neoadjuvant approach to PC. However, the optimal regimen is unclear and will likely require a precision medicine approach, ...

Keywords:

Liquid biopsy
Nab-paclitaxel
FOLFOX
Phases of clinical research
Oncology
Gemcitabine
Neoadjuvant therapy
Biomarker (medicine)
Pathology
Resectable Pancreatic Cancer
Medicine
Internal medicine
Regimen
Pancreatic cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations